Long-term benefits and risks of drug-eluting compared to bare-metal stents in patients with versus without chronic kidney disease

International Journal of Cardiology

Volumn 168, Issue 3, 2013, Pages 2381-2388

  Wanitschek, Maria ^a   Pfisterer, Matthias ^b   Hvelplund, Anders ^c   De Servi, Stefano ^d   Bertel, Osmund ^e   Jeger, Raban ^b   Rickenbacher, Peter ^f   Iversen, Allan ^c   Jensen, Jan Skov ^c   Galatius, Soeren ^c   Kaiser, Christoph ^b   Alber, Hannes ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^d University Hospital Milano   (Italy)

^e KLINIK IM PARK   (Switzerland)

^f Cardiology   (Switzerland)

Author keywords

Bare metal stent; Chronic kidney disease; Coronary artery disease; Drug eluting stent; Large coronary artery stenting; MACE rates

Indexed keywords

EVEROLIMUS; RAPAMYCIN;

ADULT; AGED; ARTICLE; BARE METAL STENT; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORONARY STENT; DRUG DELIVERY SYSTEM; DRUG ELUTING STENT; FEMALE; GLOMERULUS FILTRATION RATE; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; METAL STENT; MULTICENTER STUDY; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVASCULARIZATION; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STABLE ANGINA PECTORIS; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; CORONARY ARTERY DISEASE; MIDDLE AGED; PROSPECTIVE STUDY; PROSTHESIS; RISK ASSESSMENT; RISK FACTOR; STENT; TIME;

AGED; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; STENTS; TIME FACTORS;

EID: 84885632693     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.01.257     Document Type: Article

References (28)

1. A.S. Go, G.M. Chertow, D. Fan, C.E. McCulloch, and C.Y. Hsu Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization N Engl J Med 351 Sep 23 2004 1296 1305
2. M. Tonelli, N. Wiebe, and B. Culleton Chronic kidney disease and mortality risk: a systematic review J Am Soc Nephrol 17 2006 2034 2047
3. J.F. Mann, H.C. Gerstein, J. Pogue, J. Bosch, and S. Yusuf Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial Ann Intern Med 134 2001 629 636
4. B.F. Culleton, M.G. Larson, P.W. Wilson, J.C. Evans, P.S. Parfrey, and D. Levy Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency Kidney Int 56 1999 2214 2219
5. M.W. Yerkey, S.J. Kernis, B.A. Franklin, K.R. Sandberg, and P.A. McCullough Renal dysfunction and acceleration of coronary disease Heart 90 2004 961 966
6. P.K. Kuchulakanti, R. Torguson, and W.W. Chu Impact of chronic renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary intervention with sirolimus-eluting stents versus bare metal stents Am J Cardiol 97 2006 792 797
7. P.A. Lemos, C.A. Arampatzis, and A. Hoye Impact of baseline renal function on mortality after percutaneous coronary intervention with sirolimus-eluting stents or bare metal stents Am J Cardiol 95 2005 167 172
8. Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), European Association for Cardio-Thoracic Surgery (EACTS), and European Association for Percutaneous Cardiovascular Interventions (EAPCI) Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
9. E. Kaya, A. Cuneo, and M. Hochadel Impact of chronic kidney disease on the prognosis of patients undergoing percutaneous coronary interventions using drug-eluting stents Clin Res Cardiol 100 2011 1103 1109
10. G. Nakazawa, K. Tanabe, and J. Aoki Impact of renal insufficiency on clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents Catheter Cardiovasc Interv 69 2007 808 814
11. C. Kaiser, S. Galatius, and P. Erne Drug-eluting versus bare-metal stents in large coronary arteries N Engl J Med 363 2010 2310 2319
12. M. Pfisterer, O. Bertel, and P.O. Bonetti Drug-eluting or bare-metal stents for large coronary vessel stenting? The BASKET-PROVE (PROspective Validation Examination) trial: study protocol and design Am Heart J 155 2008 609 614
13. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2 Suppl. 1 2002 S1 S266
14. L. Mauri, W.H. Hsieh, J.M. Massaro, K.K. Ho, R. D'Agostino, and D.E. Cutlip Stent thrombosis in randomized clinical trials of drug-eluting stents N Engl J Med 356 2007 1020 1029
15. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
16. P.G. Steg, K. Huber, and F. Andreotti Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 32 2011 1854 1864
17. S.V. Rao, K. O'Grady, and K.S. Pieper A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes J Am Coll Cardiol 47 2006 809 816
18. P.J. Best, P.B. Berger, and B.R. Davis Impact of mild or moderate chronic kidney disease on the frequency of restenosis: results from the PRESTO trial J Am Coll Cardiol 44 2004 1786 1791
19. S. Yachi, K. Tanabe, and S. Tanimoto Clinical and angiographic outcomes following percutaneous coronary intervention with sirolimus-eluting stents versus bare-metal stents in hemodialysis patients Am J Kidney Dis 54 2009 299 306
20. S. Lindberg, S. Pedersen, and R. Mogelvang Prognostic utility of neutrophil gelatinase-associated lipocalin (NGAL) in predicting mortality and cardiovascular events in patients with ST-element elevation myocardial infarction treated with primary percutaneous coronary intervention J Am Coll Cardiol 60 Jul 24 2012 339 345
21. Franczyk-Skóra B, Gluba A, Banach M, Kozłowski D, Małyszko J, Rysz J. Prevention of sudden cardiac death in patients with chronic kidney disease. BMC Nephrol 2012;3(13):162.
22. M.D. Osten, J. Ivanov, and J. Eichhofer Impact of renal insufficiency on angiographic, procedural, and in-hospital outcomes following percutaneous coronary intervention Am J Cardiol 101 2008 780 785
23. M.G. Shlipak, L.F. Fried, and C. Crump Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency Circulation 107 2003 87 92
24. P. Garg, D.M. Charytan, and L. Novack Impact of moderate renal insufficiency on restenosis and adverse clinical events after sirolimus-eluting and bare metal stent implantation (from the SIRIUS trials) Am J Cardiol 106 2010 1436 1442
25. A. Halkin, R. Mehran, and C.W. Casey Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial Am Heart J 150 2005 1163 1170
26. N. Attallah, L. Yassine, K. Fisher, and J. Yee Risk of bleeding and restenosis among chronic kidney disease patients undergoing percutaneous coronary intervention Clin Nephrol 64 2005 412 418
27. F. Latif, N.S. Kleiman, and D.J. Cohen In-hospital and 1-year outcomes among percutaneous coronary intervention patients with chronic kidney disease in the era of drug-eluting stents: a report from the EVENT (Evaluation of Drug Eluting Stents and Ischemic Events) registry JACC Cardiovasc Interv 2 2009 37 45
28. A. Abdel-Latif, D. Mukherjee, P. Mesgarzadeh, and K.M. Ziada Drug-eluting stents in patients with end-stage renal disease: meta-analysis and systematic review of the literature Catheter Cardiovasc Interv 76 2010 942 948